Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 9, 2011, Pages 3761-3766

  Scaltriti, Maurizio ^a   Eichhorn, Pieter J ^a   Cortés, Javier ^a   Prudkin, Ludmila ^b   Aurac, Claudia ^b   Jiménez, José ^b   Chandarlapaty, Sarat ^c   Serra, Violeta ^a   Prat, Aleix ^a   Ibrahim, Yasir H ^a   Guzmán, Marta ^a   Gili, Magui ^a   Rodríguez, Olga ^a   Rodríguez, Sonia ^b   Pérez, José ^a   Green, Simon R ^d   Mai, Sabine ^e   Rosen, Neal ^c   Hudis, Clifford ^c   Baselga, José ^a,f  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d CYCLACEL LTD   (United Kingdom)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; TRASTUZUMAB;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; COPY NUMBER VARIATION; DRUG RESISTANCE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; MODELS, BIOLOGICAL; ONCOGENE PROTEINS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2;

EID: 79952741351     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1014835108     Document Type: Article

References (47)

1. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167. (Pubitemid 30428195)
2. Citri A, Yarden Y (2006) EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 7:505-516. (Pubitemid 44036456)
3. Slamon DJ, et al. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182. (Pubitemid 17231334)
4. Slamon DJ, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712. (Pubitemid 19147683)
5. Baselga J, Swain SM (2009) Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463-475.
6. Slamon DJ, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792. (Pubitemid 32222155)
7. Marty M, et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274. (Pubitemid 46207001)
8. Smith I, et al.; HERA study team (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36.
9. Junttila TT, et al. (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440.
10. Klapper LN, Waterman H, Sela M, Yarden Y (2000) Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60:3384-3388. (Pubitemid 30482151)
11. Scaltriti M, et al. (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28:803-814.
12. Nagata Y, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127. (Pubitemid 39485684)
13. Shin I, et al. (2002) PKB/Akt mediates cell-cycle progression by phosphorylation of p27 (Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8:1145-1152. (Pubitemid 35175970)
14. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446. (Pubitemid 30208162)
15. Berns K, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402. (Pubitemid 47539306)
16. Scaltriti M, et al. (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628-638. (Pubitemid 47073544)
17. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118-11128. (Pubitemid 41713383)
18. Shattuck DL, Miller JK, Carraway KL, 3rd, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68:1471-1477. (Pubitemid 351346855)
19. Huang X, et al. (2010) Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 70:1204-1214.
20. Mittendorf EA, et al. (2009) Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15:7381-7388.
21. Keyomarsi K, et al. (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566-1575. (Pubitemid 35315837)
22. Mittendorf EA, et al. (2010) A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 29:3896-3907.
23. Pickl M, Ries CH (2009) Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28:461-468.
24. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ (2010) HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 122:35-43.
25. Ohashi Y, Kaneko SJ, Cupples TE, Young SR (2004) Ubiquinol cytochrome c reductase (UQCRFS1) gene amplification in primary breast cancer core biopsy samples. Gynecol Oncol 93:54-58. (Pubitemid 38429549)
26. Schraml P, et al. (2003) Cyclin E overexpression and amplification in human tumours. J Pathol 200:375-382. (Pubitemid 36827312)
27. Beroukhim R, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463:899-905.
28. OhtsuboM, Theodoras AM, Schumacher J, Roberts JM, PaganoM(1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15:2612-2624.
29. Lane HA, et al. (2000) ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency. Mol Cell Biol 20:3210-3223. (Pubitemid 30215033)
30. Farley J, et al.; Gynecologic Oncology Group (2003) Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: A Gynecologic Oncology Group study. Cancer Res 63:1235-1241.
31. Berglund P, et al. (2008) Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern. J Clin Pathol 61:184-191. (Pubitemid 351218878)
32. Dhillon NK, Mudryj M (2003) Cyclin E overexpression enhances cytokine-mediated apoptosis in MCF7 breast cancer cells. Genes Immun 4:336-342. (Pubitemid 38961140)
33. Bartkova J, et al. (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444:633-637. (Pubitemid 44864442)
34. Hess KR, et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-4244. (Pubitemid 46630780)
35. Russnes HG, et al. (2010) Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2(38):38-47.
36. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL (2005) Downstream targets of growth factor and oestrogen signalling and endocrine resistance: The potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12(Suppl 1):S47-S59. (Pubitemid 41395413)
37. Porter PL, et al. (2006) p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 98:1723-1731. (Pubitemid 44942710)
38. Potemski P, et al. (2006) Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. J Exp Clin Cancer Res 25:59-64.
39. Le XF, et al. (2006) Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle 5:1654-1661.
40. Sherr CJ (1994) G1 phase progression: Cycling on cue. Cell 79:551-555.
41. Geng Y, et al. (2003) Cyclin E ablation in the mouse. Cell 114:431-443. (Pubitemid 37100992)
42. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ (2004) P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64: 3981-3986. (Pubitemid 38697313)
43. Le XF, et al. (2003) The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278: 23441-23450.
44. Akli S, et al. (2007) Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67:7212-7222. (Pubitemid 47206549)
45. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE (1997) Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 11:1464-1478.
46. Wartenberg M, Fischer K, Hescheler J, Sauer H (2002) Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors. Biochim Biophys Acta 1589:49-62. (Pubitemid 34242901)
47. Eichhorn PJ, et al. (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/ phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68:9221-9230.